A Promising New Approach To Reduce Repeat Surgeries for Subdural Hematomas: Jason M. Davies, MD, PhD
The assistant professor of neurosurgery and biomedical informatics at the State University of New York at Buffalo talked about the potential of embolizing the middle meningeal artery in patients with subdural hematomas. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
"We're on the cusp of a paradigm shift...the goal here is to reduce the number of maximum invasive procedures that we're doing."
The EMBOLISE (NCT04402632) trial evaluated the safety and efficacy of the Onyx Liquid Embolic System (LES) embolization of the middle meningeal artery (MMA) as an adjunct to conventional treatment for symptomatic subacute or chronic subdural hematomas (SDH). The study included 400 patients, randomly assigned 1:1 to either surgery alone or surgery with adjunctive MMA embolization, across 39 US centers to assess the rate of hematoma recurrence/progression requiring surgical drainage and composite functional decline in 90 days post-treatment.
Prior data presented from the trial showed that treatment using the embolization system resulted in a 3-fold decrease in the rate of hematoma recurrence/progression requiring surgical drainage, the primary end point, at 90 days. At the 2024 American Academy of Neurology (AAN) Annual Meeting, held April 13-18, in Denver, Colorado, Jason M. Davies, MD, PhD, presented on the latest clinical trial findings from EMBOLISE in a clinical trial plenary session. The session covered landmark clinical trials, including EMBOLISE, that impact patient care in every subspecialty of neurology, including stroke.
Davies, an assistant professor of neurosurgery and biomedical informatics at the State University of New York at Buffalo, sat down with NeurologyLive® at the meeting to further dive into the primary aim of this new approach to treat SDH. He spoke about how the embolization of the MMA impacts the recurring rates of SDH among the participants, as well as the potential benefits of this new approach and what it may offer for older patients who undergo treatment for SDH.
Click here for more coverage of AAN 2024.
REFERENCES
1. Bove R, Pietrasanta C, Oreja-Guevara C, et al. Pregnancy and Infant Outcomes in Females Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of over 3,000 Pregnancies to Date. Presented at: 2024 AAN Annual Meeting; April 13-18; Denver, CO.
